)
)
Merus Investor Relations Material
Latest events
Study Update
Merus
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Merus N.V.
Access all reports
Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. The company specializes in creating full-length human multispecific antibodies known as Biclonics and Triclonics, which are designed to engage multiple targets, offering new approaches to treat various cancers. Merus has a broad pipeline, including candidates in different stages of clinical trials targeting solid tumors and hematologic malignancies. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the Nasdaq.
Key slides for Merus N.V.
Study Update
Merus N.V.
Study Update
Merus N.V.
Latest articles
)
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
)
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
)
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
MRUS
Country
🇺🇸 United States